Fortrea (FTRE) – Analysts’ Recent Ratings Changes

A number of firms have modified their ratings and price targets on shares of Fortrea (NASDAQ: FTRE) recently:

• 8/4/2026 – Fortrea had its price target raised by TD Cowen from $19.00 to $23.00. They now have a “buy” rating on the stock.
• 8/4/2026 – Fortrea was downgraded by Zacks Research from “strong-buy” to “hold”.
• 8/1/2026 – Fortrea was upgraded by Wall Street Zen from “hold” to “buy”.
• 7/31/2026 – Fortrea had its price target raised by Citigroup Inc. from $20.00 to $22.00. They now have a “buy” rating on the stock.
• 7/30/2026 – Fortrea had its “hold” rating reaffirmed by Deutsche Bank Aktiengesellschaft. They now have a $20.00 price target on the stock.
• 7/30/2026 – Fortrea was given a new $23.00 price target by Robert W. Baird.
• 7/30/2026 – Fortrea had its price target raised by Barclays PLC from $18.00 to $22.00. They now have an “equal weight” rating on the stock.
• 7/30/2026 – Fortrea had its price target raised by Truist Financial Corporation from $19.00 to $26.00. They now have a “buy” rating on the stock.
• 7/29/2026 – Fortrea had its “outperform” rating reaffirmed by Evercore Inc.
• 7/29/2026 – Fortrea was upgraded by William Blair to “hold”.
• 7/21/2026 – Fortrea was downgraded by Wall Street Zen from “buy” to “hold”.
• 7/17/2026 – Fortrea had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/13/2026 – Fortrea had its price target raised by Mizuho from $13.00 to $16.00. They now have a “neutral” rating on the stock.
• 7/13/2026 – Fortrea was upgraded by Wall Street Zen from “hold” to “buy”.
• 7/6/2026 – Fortrea was upgraded by Zacks Research from “hold” to “strong-buy”.
• 7/5/2026 – Fortrea was downgraded by Wall Street Zen from “buy” to “hold”.
• 6/27/2026 – Fortrea was upgraded by Wall Street Zen from “hold” to “buy”.
• 6/24/2026 – Fortrea had its price target raised by Barclays PLC from $16.00 to $18.00. They now have an “equal weight” rating on the stock.

Insider Buying and Selling

In other news, CEO Anshul Thakral sold 99,869 shares of the stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $19.16, for a total value of $1,913,490.04. Following the completion of the transaction, the chief executive officer owned 316,797 shares of the company’s stock, valued at approximately $6,069,830.52. This represents a 23.97% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 0.73% of the company’s stock.

Fortrea, Inc is a global contract development and manufacturing organization (CDMO) that provides integrated solutions for pharmaceutical and biotechnology companies. Established as a spin-off from Thermo Fisher Scientific’s Pharma Services business in October 2023, Fortrea leverages a legacy of scientific expertise and manufacturing scale to support drug development from early-stage research through commercial production. The company’s comprehensive offerings address the complex needs of both small-molecule and biologics programs, making it a single source for clients seeking to accelerate timelines and manage costs.

Fortrea’s core services encompass analytical and formulation development, process optimization, clinical and commercial manufacturing, and packaging services.